Yunu, a provider of clinical trial imaging workflow and data management solutions, has partnered with WCG, a global leader in clinical trial solutions, in support of WCG’s imaging services. WCG is one of the world’s largest clinical services organizations, providing solutions that directly impacted 93% of all FDA-approved therapeutics last year.
Yunu manages more than 5,000 active clinical trial protocols and serves as the primary source of imaging endpoint data for over 25% of all NCI-designated cancer centers. The partnership between Yunu and WCG enables the companies to revolutionize their capabilities in trial imaging, providing sponsors and sites with enhanced support to ensure accurate, efficient, and transparent clinical trials.
With Yunu’s advanced platform, WCG has expanded its ability to support critical imaging workflows for trial sponsors, offering real-time transparency to highly accurate trial imaging data. The platform provides support for WCG imaging services, eliminating ineffective and redundant systems, streamlining imaging services, further decreasing start-up timelines, and creating a robust foundation for managing larger, more complex prospective trial workflows while also accelerating their growing portfolio of imaging AI validation trials.
Through this collaboration, Yunu empowers WCG to provide a differentiated experience for sponsors, where they can:
- See Everything: Access live insights and analytics for greater control over trial progress.
- Collaborate Freely: Communicate with all trial stakeholders through a common platform.
- Move Faster: Streamline processes and minimize inefficiencies to deliver expedited, more effective trials.
WCG also offers Yunu capabilities to trial sites, harmonizing workflow and supplying critical imaging assessment tools that ensure compliance with each trial’s specific protocol. Leveraging Yunu to deliver imaging accuracy at the source eliminates downstream delays and site-central discordance. Cancer centers are already rapidly adopting the Yunu platform for imaging across all trials to improve trial imaging accuracy, patient qualification and retention, and to gain insights from earlier tumor response signals.
Both Yunu (Booth #106) and WCG (Booth #803) will be exhibiting at SCOPE 2025, February 3-6 in Orlando, Florida.
For more information, visit yunu.io or wcgclinical.com.
September 15, 2026 
